αL-Integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 288, Issue 1 51-1, 2005, Pages

  Huang, Meng ^a   Matthews, Kametra ^a   Siahaan, Teruna J ^b   Kevil, Christopher G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Diabetes; Leukocyte; Lymphocyte function associated antigen 1; Pancreas

Indexed keywords

ALPHA1 INTEGRIN; BETA INTEGRIN; BETA1 INTEGRIN; CYCLIC PEPTIDE ANTAGONIST; CYCLOPEPTIDE; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL ADHESION; CELL INTERACTION; CELL SURFACE; CONTROLLED STUDY; DIABETES MELLITUS; HYDRODYNAMICS; MONOCYTE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE;

ANIMALS; CELL ADHESION; DIABETES MELLITUS, TYPE 1; INTEGRIN ALPHA1; INTEGRINS; ISLETS OF LANGERHANS; MICE; MONOCYTES; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 10844268104     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00267.2004     Document Type: Article

References (52)

1. Anderson M and Siahaan T. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24: 487-501, 2003.
2. Bertry-Coussot L, Lucas B, Danel C, Halbwachs-Mecarelli L, Bach JF, Chatenoud L, and Lemarchand P. Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway. J Immunol 168: 3641-3648, 2002.
3. Dunne JL, Ballantyne CM, Beaudet AL, and Ley K. Control of leukocyte rolling velocity in TNF-α induced inflammation by LFA-1 and Mac-1. Blood 99: 336-341, 2002.
4. Durinovic-Bello I. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Autoimmunity 27: 159-177, 1998.
5. Edwards CP, Fisher KL, Presta LG, and Bodary SC. Mapping the intercellular adhesion molecule-1 and -2 binding site on the inserted domain of leukocyte function-associated antigen-1. J Biol Chem 273: 28937-28944, 1998.
6. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360-1368, 1986
7. 4, and L-selectin mediate T-cell homing to the pancreas in the model of adoptive transfer of diabetes in NOD mice. Diabetes 45: 1181-1186, 1996.
8. Faveeuw C, Gagnerault MC, and Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of non-obese-diabetic mice. J Immunol 152: 5969-5978, 1994.
9. Griggs DW, Schmidt CM, and Carron CP. Characteristics of cation binding to the I domains of LFA-1 and MAC-1. J Biol Chem 273: 22113-22119, 1998.
10. Hanninen A, Salmi M, Simell O, and Jalkanen S. Endothelial cell-binding properties of lymphocytes infiltrated into human diabetic pancreas. Implications for pathogenesis of IDDM. Diabetes 42: 1656-1662, 1993.
11. Harris ES, McIntyre TM, Prescott SM, and Zimmerman GA. The leukocyte integrins. J Biol Chem 275: 23409-23412, 2000.
12. Henderson RB, Lim LH, Tessier PA, Gavins FN, Mathies M, Perretti M, and Hogg N. The use of lymphocyte function associated antigen (LFA)-1-deficient mice to determine the role of LFA-1, Mac-1, and α4-integrin in the inflammatory response of neutrophils. J Exp Med 194: 219-226, 2001.
13. Herold K, Burton J, Francois F, Poumian-Ruiz E, Glandt M, and Bluestone J. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1 (Ala-Ala). J Clin Invest 111: 409-418, 2003.
14. Herold K, Hagopian W, Auger J, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman S, Harlan D, Xu D, Zivin R, and Bluestone J. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698, 2002.
15. Hutchings P, Rosen H, O'Reilly L, Simpson E, Gordon S, and Cooke A. Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 348: 639-642, 1990.
16. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, Iwahashi H, Yamagata K, Waguri M, Nanmo T, Uno S, Nakajima H, Namba M, Kawata S, Miyagawa JI, and Matsuzawa Y. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 50: 1269-1273, 2001.
17. Irawaty W, Kay T, and Thomas H. Transmembrane TNF and IFN-γ induce caspase independent death of primary mouse pancreatic β-cells. Autoimmunity 35: 369-375, 2002.
18. Kevil C and Bullard D. Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Am J Med 106: 677-687, 1999.
19. Kevil CG. Endothelial cell activation in inflammation: lessons from mutant mouse models. Pathophysiology 9: 63-74, 2003.
20. Kevil CG and Bullard DC. Cell adhesion molecules in the rheumatic diseases. In: Arthritis and Allied Conditions, edited by Koopman W. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 478-489.
21. Kevil CG, Chidlow JH, Bullard DC, and Kucik DF. High-temporal-resolution analysis demonstrates that ICAM-I stabilizes WEHI 274.1 monocytic cell rolling on endothelium. Am J Physiol Cell Physiol 285: C112-C118, 2003.
22. Kim M, Carman CV, and Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 301: 1720-1725, 2003.
23. Knorr R and Dustin ML. The lymphocyte function associated antigen 1 I domain is a transient binding module for intercellular adhesion molecule-1 (ICAM-1) and ICAM-3 in hydrodynamic flow. J Exp Med 186: 719-730, 1997.
24. Kucik DF, Dustin ML, Miller JM, and Brown EJ. Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. J Clin Invest 97: 2139-2144, 1996.
25. Lamhamedi-Cherradi S, Zheng S, Tisch R, and Chen Y. Critical roles of tumor necrosis factor related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52: 2274-2278, 2003.
26. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, and Martin S. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 41: 1668-1671, 1992.
27. Lee JO, Rieu P, Arnaout MA, and Liddingtone R. Crystal structure of the A domain from the α-subunit of integrin CR3 (CD11b/CD18). Cell 80: 631-638, 1995.
28. Martin S. Soluble adhesion molecules in type 1 diabetes mellitus. Horm Metab Res 29: 639-642, 1997.
29. Martin S, Hibino T, Faust A, Kleemann R, and Kolb H. Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune insulitis of NOD mice and association with both Th1- and Th2-type infiltrates. J Autoimmun 9: 637-643, 1996.
30. Martin S, van den Engel NK, Vinke A, Heidenthal E, Schulte B, and Kolb H. Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J Autoimmun 17: 109-117, 2001.
31. 4-integrins in the development of insulin-dependent diabetes mellitus. Curr Top Microbiol Immunol 231: 65-83, 1998.
32. 1, integrin, peripheral node addressin/L-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol 159: 671-681, 2001.
33. Mysliwiec J, Kretowski A, Kinalski M, and Kinalska I. CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects. Immunol Lett 70: 69-72, 1999.
34. Ni N, Kevil CG, Bullard DC, and Kucik DF. Avidity modulation activates adhesion under flow and requires cooperativity among adhesion receptors. Biophys J 85: 4122-4133, 2003.
35. Notkins AL and Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108: 1247-1252, 2001.
36. Roep BO, Heidenthal E, de Vries RR, Kolb H, and Martin S. Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet 343: 1590-1593, 1994.
37. Salas A, Shimaoka M, Chen S, Carman CV, and Springer T. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lympocyte function associated antigen-1. J Biol Chem 277: 50255-50262, 2002.
38. Shimaoka M and Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2: 703-716, 2003.
39. Shimaoka M, Xiao T, Liu JH, Yang Y, Dong Y, Jun CD, McCormack A, Zhang R, Joachimiak A, Takagi J, Wang JH, and Springer TA. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112: 99-111, 2003.
40. Sigal A, Bleijs DA, Grabovsky V, van Vliet SJ, Dwir O, Figdor CG, Kooyk Yv, and Alon R. The LFA-1 integrin supports rolling adhesions on ICAM-1 under physiological shear flow in a permissive cellular environment. J Immunol 165: 442-452, 2000.
41. Springer TA. Predicted and experimental structures of integrins and beta propellers. Curr Opin Struct Biol 12: 802-813, 2002.
42. + T cells in autoimmune diabetes through the use of TCR transgenic mice. Immunol Rev 169: 55-65, 1999.
43. Takagi J and Springer TA. Integrin activation and structural rearrangement. Immunol Rev 186: 141-163, 2002.
44. Thomas HE and Kay TW. Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic mouse. Diabetes Metab Res Rev 16: 251-261, 2000.
45. Tibbetts S, Jois S, Siahaan T, Benedict S, and Chan M. Linear and cyclic LFA-1 and ICAM-1 peptides inhibit cell adhesion and function. Peptides 21: 1161-1167, 2001.
46. Toyoda H and Formby B. Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model. Bioessays 20: 750-757, 1998.
47. Woska JR, Last-Barney K, Rothlein R, Kroe RR, Reilly PL, Jeanfavre DD, Mainofli EA, Kelly TA, Caviness GO, Fogal SE, Panzenbeck MJ, Kishimoto TK, and Giblin PA. Small molecule LFA-1 antagonists compete with an anti-LFA-1 monoclonal antibody for binding to the CD11a I domain: development of a flow-cytometry-based receptor occupancy assay. J Immunol Methods 277: 101-115, 2003.
48. + T cell levels in NOD mice. Proc Natl Acad Sci USA 99: 12287-12292, 2002.
49. Xu C, Yusuf-Makagiansar H, Hu Y, Jois S, and Siahaan T. Structural and ICAM-1 docking properties of a cyclic peptide from the I domain of LFA-1: an inhibitor of ICAM-1/LFA-1 mediated T cell adhesion. J Biolmol Struct Dyn 19: 789-799, 2002.
50. Yalamanchili P, Lu C, Oxvig C, and Springer TA. Folding and function of I domain deleted Mac-1 and lymphocyte function associated antigen-1. J Biol Chem 275: 21877-21882, 2000.
51. Yusuf-Makagiansar H, Makagiansar I, and Siahaan T. Inhibition of the adherence of T lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function associated antigen-1. Inflammation 25: 203-214, 2001.
52. Yusuf-Makagiansar H and Siahaan T. Binding and internalization of an LFA-1 derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1 expressing cells. Pharm Res 18: 329-335, 2001.